Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Drug Test Anal. 2016 Aug 4;9(1):68–74. doi: 10.1002/dta.2036

Table 3.

Case-patients who Reported Consuming OxyELITE Pro™ by Source of Identification and Other Supplement Use — United States, 2013 (n = 25)

Identified through NPDS or FDA MedWatch n (%) Identified by DoD, state health department, or CDC Hotline n (%) Overall n (%)
Consumed only OxyELITE Pro™ 3 (23.1) 4 (33.3) 7 (28.0)
Consumed OxyELITE Pro™ and another supplement 5 (38.5) 7 (58.3) 12 (48.0)
Incomplete information on supplement use other than OxyELITE Pro™ 5 (38.5) 1 (8.3) 6 (24.0)